Trulicity drug class
Pro Research Analysisby 
Searched over 200M research papers
Trulicity Drug Class: An Overview of Dulaglutide
Introduction to Dulaglutide (Trulicity)
Dulaglutide, marketed under the brand name Trulicity, is a medication developed by Eli Lilly and Company for the treatment of type 2 diabetes mellitus. It is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, which means it mimics the action of the GLP-1 hormone to help regulate blood sugar levels .
Mechanism of Action: GLP-1 Receptor Agonist
Dulaglutide functions by activating GLP-1 receptors, which play a crucial role in glucose metabolism. By stimulating these receptors, dulaglutide enhances insulin secretion in response to meals, suppresses glucagon release, and slows gastric emptying, thereby improving glycemic control 124. This mechanism helps in lowering both fasting and postprandial glucose levels, making it effective in managing type 2 diabetes .
Efficacy and Safety in Clinical Trials
Clinical trials, particularly the AWARD program, have demonstrated the efficacy and safety of dulaglutide. In these trials, dulaglutide showed superior glucose-lowering activity compared to other diabetes medications such as metformin, sitagliptin, exenatide, and insulin glargine. It was also found to be non-inferior to liraglutide 23. Additionally, dulaglutide has been shown to lower glycated hemoglobin (A1c) levels, promote weight loss, and improve β-cell function .
Cardiovascular and Metabolic Benefits
Beyond glycemic control, dulaglutide offers cardiovascular benefits, including lower blood pressure and improved lipid profiles. These additional benefits make it a valuable option for patients with type 2 diabetes who are at risk of cardiovascular diseases . The drug also has a low risk of hypoglycemia, which is a significant advantage over some other diabetes treatments .
Administration and Dosage
Dulaglutide is administered as a subcutaneous injection once weekly, with available doses of 0.75 mg and 1.5 mg. This once-weekly regimen improves patient compliance compared to daily medications 23.
Use in Special Populations: Obesity
Dulaglutide has also shown promise in treating morbid obesity. In a case report, a patient with long-standing obesity achieved significant weight loss and improved well-being after switching to dulaglutide . This suggests potential future applications of dulaglutide in obesity management, pending further research and regulatory approval.
Conclusion
Dulaglutide (Trulicity) is a GLP-1 receptor agonist that has proven effective in managing type 2 diabetes by improving glycemic control, promoting weight loss, and offering cardiovascular benefits. Its once-weekly administration and favorable safety profile make it a convenient and effective option for patients. As research continues, dulaglutide may also find broader applications in treating conditions like obesity.
Sources and full results
Most relevant research papers on this topic